Mohamed Sorror

Honored to share that PCORI has selected for funding a five-year, $15.1M project I will lead to compare upfront allogeneic HCT with contemporary non-transplant therapy for older adults with #AML in remission.

pcori.org/news-release/2…

Excited and honored to share the stand tomorrow with Dr. Giralt, whom I have known for 2 decades, to debate transplant versus no-transplant for older, medically infirm patients with p53 MDS. To top it, I will also debate with my friend Dr. Andy Artz the same question but for younger older pts with multiple comorbidities. I am hoping it will turn to be one of the most interesting sessions I participated in and really appreciative to my colleagues in the Aging SIG for this invitation #TCT2026

Great initiative from @TheLancet in the current dark atmosphere for science and medical care. I hope other high rank journals follow suit and our community has a unified stance behind our goals and vision.

We extremely excited and honored for our study on the impact of social determinants of health on mortality and access to alloegenic hematopoietic cell transplantation for AML to be selected for a Plenary Scientific Session Presentation at ASH 2024 in San Diego CA. This is a first step to try to achieve equity in chances to cure AML for all patients regardless of their background. More to come in the future. Congratulations Dr. Natalie Wuliji for being the first author and presenter of tue abstract.

Session about statistical analyses for transplant and cellular therapy. Tandem Meetings 2024